Impact of ALDH1A1 Expression in Intrahepatic Cholangiocellular Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2025 Jan 2

PMID 39744576

Authors

Konrad Kurowski

Melanie Foll

Tilman Werner

Oliver Schilling

Martin Werner

Stefan Fichtner-Feigl

Bertram Bengsch

Peter Bronsert

Philipp Anton Holzner

Sylvia Timme

Affiliations

Soon will be listed here.

Abstract

Intrahepatic cholangiocarcinoma (iCC) is a rare malignant liver tumor with limited therapeutic advancements. Despite its increasing global incidence knowledge of treatment options remains stagnant, leading to poor five-year patient survival rates and high recurrence post-surgery. ALDH1A1, a member of the ALDH superfamily, is associated with cancer stem cells and has conflicting reports regarding its prognostic role in iCC. This retrospective study analyzed 69 iCC patient samples from University Hospital Freiburg. Tissue microarrays (TMAs) were constructed, and ALDH1A1 expression was immunohistochemically assessed using machine learning algorithms. Script-based Survival analysis employed Kaplan-Meier curves, log-rank tests, and Cox Proportional Hazards Models. ALDH1A1 overexpression, both in tumor and stromal cells, correlates with favorable overall survival in iCC. Gender-specific analyses indicate a more pronounced effect in females. These findings suggest ALDH1A1 as a potential prognostic biomarker in iCC, warranting further validation in larger cohorts and exploration as a therapeutic target.

References

Macias R, Kornek M, Rodrigues P, Paiva N, Castro R, Urban S . Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:108-122. DOI: 10.1111/liv.14090. View

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

Elenbaas B, Weinberg R . Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001; 264(1):169-84. DOI: 10.1006/excr.2000.5133. View

Penumatsa K, Edassery S, Barua A, Bradaric M, Luborsky J . Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res. 2010; 3:28. PMC: 3022900. DOI: 10.1186/1757-2215-3-28. View

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

Tanei T, Morimoto K, Shimazu K, Kim S, Tanji Y, Taguchi T . Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009; 15(12):4234-41. DOI: 10.1158/1078-0432.CCR-08-1479. View

Clark G, Zborowski D, Culbertson J, Whitehead M, Savoie M, Seymour L . Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2007; 1(8):837-46. View

Landen Jr C, Goodman B, Katre A, Steg A, Nick A, Stone R . Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010; 9(12):3186-99. PMC: 3005138. DOI: 10.1158/1535-7163.MCT-10-0563. View

Goliwas K, Deshane J, Elmets C, Athar M . Moving Immune Therapy Forward Targeting TME. Physiol Rev. 2020; 101(2):417-425. PMC: 8428923. DOI: 10.1152/physrev.00008.2020. View

10.

Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M . Liver fluke induces cholangiocarcinoma. PLoS Med. 2007; 4(7):e201. PMC: 1913093. DOI: 10.1371/journal.pmed.0040201. View

11.

Braun T, Bober E, Singh S, Agarwal D, GOEDDE H . Evidence for a signal peptide at the amino-terminal end of human mitochondrial aldehyde dehydrogenase. FEBS Lett. 1987; 215(2):233-6. DOI: 10.1016/0014-5793(87)80152-7. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Brandi G, Di Girolamo S, Farioli A, De Rosa F, Curti S, Pinna A . Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control. 2013; 24(5):911-8. PMC: 3631123. DOI: 10.1007/s10552-013-0167-3. View

14.

Mayer S, Milo T, Isaacson A, Halperin C, Miyara S, Stein Y . The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts. Nat Commun. 2023; 14(1):5810. PMC: 10509226. DOI: 10.1038/s41467-023-41518-w. View

15.

Banales J, Marin J, Lamarca A, Rodrigues P, Khan S, Roberts L . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9):557-588. PMC: 7447603. DOI: 10.1038/s41575-020-0310-z. View

16.

Ballman K . Biomarker: Predictive or Prognostic?. J Clin Oncol. 2015; 33(33):3968-71. DOI: 10.1200/JCO.2015.63.3651. View

17.

Palmer W, Patel T . Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; 57(1):69-76. PMC: 3804834. DOI: 10.1016/j.jhep.2012.02.022. View

18.

Bednarz-Knoll N, Nastaly P, Zaczek A, Stoupiec M, Riethdorf S, Wikman H . Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. Oncotarget. 2015; 6(29):26789-803. PMC: 4694953. DOI: 10.18632/oncotarget.4628. View

19.

Kahlert C, Bergmann F, Beck J, Welsch T, Mogler C, Herpel E . Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer. 2011; 11:275. PMC: 3135572. DOI: 10.1186/1471-2407-11-275. View

20.

Peltanova B, Raudenska M, Masarik M . Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer. 2019; 18(1):63. PMC: 6441173. DOI: 10.1186/s12943-019-0983-5. View